Fichtner, Urs A.; Arslanow, Anita; Binder, Harald et al.
How do (false) positively screened patients experience a screening programme for liver cirrhosis or fibrosis in Germany? A qualitative studyHEALTH EXPECTATIONS. Bd. 26. H. 5. 2023 S. 1923-1930
Koch, Martina; Zecher, Daniel; Lopau, Kai et al.
Human Leucocyte Antigen-Matching Can Improve Long Term Outcome of Renal Allografts from Donors Older Than 75 YearsTRANSPLANTATION PROCEEDINGS. Bd. 55. H. 2. 2023
Kudo, Masatoshi; Finn, Richard S. S.; Galle, Peter R. R. et al.
IMbrave150: Efficacy and Safety of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma-An Exploratory Analysis of the Phase III StudyLIVER CANCER. Bd. 12. H. 3. 2023 S. 238-250
Kudo, Masatoshi; Tsuchiya, Kaoru; Shao, Yu Yun et al.
IMbrave150: Exploratory analysis to examine the association between bevacizumab (bev) ever being skipped and bev never being skipped in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) plus bev in a global phase 3 study.JOURNAL OF CLINICAL ONCOLOGY. Bd. 41. 2023 S. 538-538
Kudo, Masatoshi; Tsuchiya, Kaoru; Shao, Yu-Yun et al.
Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 studyLIVER CANCER. 2023
Vithayathil, Mathew; D'Alessio, Antonio; Fulgenzi, Claudia Angela Maria et al.
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinomaHEPATOLOGY INTERNATIONAL. Bd. 17. H. 4. 2023 S. 904-914
Michel, Maurice; Doll, Michelle; Armandi, Angelo et al.
Impairment of health-related quality of life among people with type 2 diabetes and advanced fibrosisJOURNAL OF HEPATOLOGY. Bd. 78. 2023 S. S618-S619
Dietz-Fricke, Christopher; Tacke, Frank; Zoellner, Caroline et al.
Improvements in ALT levels during Bulevirtide treatment for hepatitis D are seen regardless of virologic responseJOURNAL OF HEPATOLOGY. Bd. 78. 2023 S. S1139-S1140
Schneider, Paul; Capeloa, Leon; Zhang, Heyang et al.
In vivo cancer-associated fibroblast specific gene silencing for anti-stromal therapy in primary liver cancer using novel siRNA loaded polypeptoide nanoparticlesJOURNAL OF HEPATOLOGY. Bd. 78. 2023 S. S28-S29
Lam, Lyn Ley; Pavlakis, Nick; Shitara, Kohei et al.
INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)BMC CANCER. Bd. 23. H. 1. 2023